公开(公告)号：US20160166679A1

公开(公告)日：2016-06-16

申请号：US14966530

申请日：2015-12-11

Applicant: Purdue Research Foundation

Inventor： Philip S. Low ,  Nimalka A. Bandara

IPC: A61K39/385 ,  A61K31/403 ,  A61K31/4439 ,  A61K39/39 ,  A61K47/48

CPC classification number: A61K39/385 ,  A61K31/404 ,  A61K31/4439 ,  A61K39/0005 ,  A61K45/06 ,  A61K47/551 ,  A61K47/643 ,  A61K47/646 ,  A61K51/0459 ,  A61K51/0497 ,  A61K2039/545 ,  A61K2039/55577 ,  A61K2039/55583 ,  A61K2039/585 ,  A61K2039/6012 ,  A61K2039/6081 ,  A61K2039/804 ,  A61K2039/86 ,  A61K2039/868 ,  A61K2300/00

Abstract: The invention relates to a method of treating a cancer, the method comprising the steps of administering to a patient an immunogen conjugate, administering to the patient a folate conjugate comprising a folate linked to a hapten, and administering to the patient a tyrosine kinase inhibitor.

Abstract translation: 本发明涉及一种治疗癌症的方法，所述方法包括以下步骤：向患者施用免疫原缀合物，向患者施用包含与半抗原连接的叶酸的叶酸缀合物，以及向患者施用酪氨酸激酶抑制剂。

公开(公告)号：US09341629B2

公开(公告)日：2016-05-17

申请号：US14715799

申请日：2015-05-19

Applicant: Purdue Research Foundation

Inventor： Sumith A. Kularatne ,  Sakkarapalayam M. Mahalingam ,  Philip S. Low

IPC: A61B5/00 ,  A61B8/00 ,  A61B10/00 ,  G01N33/574 ,  C07D475/04 ,  G01N33/58 ,  A61K49/00

CPC classification number: A61K49/0052 ,  A61K49/001 ,  A61K49/0021 ,  A61K49/0032 ,  A61K49/0034 ,  C07D475/04 ,  G01N21/6428 ,  G01N33/5091 ,  G01N33/566 ,  G01N33/56966 ,  G01N33/57492 ,  G01N33/582 ,  G01N33/6893 ,  G01N2021/6432 ,  G01N2021/6439 ,  G01N2201/061 ,  G01N2333/705 ,  G01N2800/24

Abstract: The present disclosure relates to compounds that are useful as near-infrared fluorescence probes, wherein the compounds include i) a pteroyl ligand that binds to a target receptor protein, ii) a dye molecule, and iii) a linker molecule that comprises an amino acid or derivative thereof. The disclosure further describes methods and compositions for making and using the compounds, methods incorporating the compounds, and kits incorporating the compounds.

公开(公告)号：US08916167B2

公开(公告)日：2014-12-23

申请号：US13795059

申请日：2013-03-12

Applicant: Purdue Research Foundation

Inventor： Philip S. Low ,  Mary J. Turk

IPC: A61K39/385 ,  A61K35/26 ,  A61K51/04 ,  A61K9/127 ,  A61K47/48 ,  A61K51/10

CPC classification number: A61K51/0482 ,  A61K9/127 ,  A61K47/646 ,  A61K47/6849 ,  A61K51/1027

Abstract: The invention relates to a method of treating or monitoring/diagnosing a disease state mediated by activated macrophages. The method comprises the step of administering to a patient suffering from a macrophage mediated disease state an effective amount of a composition comprising a conjugate or complex of the general formula Ab-X where the group Ab comprises a ligand capable of binding to activated macrophages, and when the conjugate is being used for treatment of the disease state, the group X comprises an immunogen, a cytotoxin, or a compound capable of altering macrophage function, and when the conjugate is being used for monitoring/diagnosing the disease state, X comprises an imaging agent. The method is useful for treating a patient suffering from a disease selected from the group consisting of rheumatoid arthritis, ulcerative colitis, Crohn's disease, inflammation, infections, osteomyelitis, atherosclerosis, organ transplant rejection, pulmonary fibrosis, sarcoidosis, and systemic sclerosis.

Abstract translation: 本发明涉及一种治疗或监测/诊断由活化的巨噬细胞介导的疾病状态的方法。 该方法包括向患有巨噬细胞介导的疾病状态的患者施用有效量的包含通式Ab-X的缀合物或复合物的组合物，其中基团Ab包含能够结合活化的巨噬细胞的配体，以及 当缀合物用于治疗疾病状态时，组X包含免疫原，细胞毒素或能够改变巨噬细胞功能的化合物，并且当所述缀合物用于监测/诊断疾病状态时，X包括 成像剂。 该方法可用于治疗患有选自类风湿性关节炎，溃疡性结肠炎，克罗恩病，炎症，感染，骨髓炎，动脉粥样硬化，器官移植排斥，肺纤维化，结节病和系统性硬化症的疾病的患者。

公开(公告)号：US20140271476A1

公开(公告)日：2014-09-18

申请号：US14207130

申请日：2014-03-12

Applicant: Purdue Research Foundation

Inventor： Sumith A. Kularatne ,  Sakkarapalayam M. Mahalingam ,  Philip S. Low

IPC: A61K49/00 ,  G01N33/566 ,  G01N33/569

CPC classification number: A61K49/0052 ,  A61K49/001 ,  A61K49/0021 ,  A61K49/0032 ,  A61K49/0034 ,  C07D475/04 ,  G01N21/6428 ,  G01N33/5091 ,  G01N33/566 ,  G01N33/56966 ,  G01N33/57492 ,  G01N33/582 ,  G01N33/6893 ,  G01N2021/6432 ,  G01N2021/6439 ,  G01N2201/061 ,  G01N2333/705 ,  G01N2800/24

Abstract: The present disclosure relates to compounds that are useful as near-infrared fluorescence probes, wherein the compounds include i) a pteroyl ligand that binds to a target receptor protein, ii) a dye molecule, and iii) a linker molecule that comprises an amino acid or derivative thereof. The disclosure further describes methods and compositions for making and using the compounds, methods incorporating the compounds, and kits incorporating the compounds.

Abstract translation: 本公开涉及可用作近红外荧光探针的化合物，其中所述化合物包括i）与靶受体蛋白结合的蝶啶配体，ii）染料分子，和iii）包含氨基酸的连接分子 或其衍生物。 本公开进一步描述了制备和使用化合物的方法和组合物，并入化合物的方法，以及并入化合物的试剂盒。

公开(公告)号：US12150981B2

公开(公告)日：2024-11-26

申请号：US17387892

申请日：2021-07-28

Applicant: Purdue Research Foundation

Inventor： Philip S. Low ,  Haiyan Chu ,  Yong Gu Lee

IPC: A61K47/54 ,  A61K35/17 ,  A61K39/00 ,  A61K47/55 ,  A61K47/60 ,  A61K47/69

Abstract: Cytotoxic lymphocytes expressing chimeric antigen receptors (CAR) that target and bind small conjugate molecules (SCM) are disclosed, as well as methods of using the cells and the SCMs in the treatment of cancer.

公开(公告)号：US11623009B2

公开(公告)日：2023-04-11

申请号：US16927773

申请日：2020-07-13

Applicant: Purdue Research Foundation ,  University of Utah

Inventor： Stewart Andrew Low ,  Philip S. Low ,  Christopher Galliford ,  Jindrich Kopecek ,  Jiyan Yang

IPC: A61K47/42 ,  A61L27/22 ,  A61K9/107 ,  A61K31/404 ,  C07D403/04 ,  C07D209/34 ,  C07D487/00 ,  A61L27/54 ,  C07K7/06 ,  C07K7/08 ,  A61P19/00 ,  A61M5/00

Abstract: Aspects of the present disclosure generally relate to compounds for targeting and healing bone fractures. Some of these compounds include a negatively charged oligopeptide comprising an acidic oligopeptide, a linker, which may be hydrolyzable or may be a substrate for the protease cathepsin K, and at least one molecule that promotes bone healing. In some compounds the molecule that promotes bone healing is an anabolic compound that inhibits GSK3β, in some compounds the molecule that promotes the healing of bone fracture is a pro-inflammatory agent such as PGE1. Other embodiments include methods of treating a bone fracture comprising administering a therapeutic amount of any one of the compounds disclosed herein.

公开(公告)号：US11524082B2

公开(公告)日：2022-12-13

申请号：US16640539

申请日：2018-08-21

Applicant: PURDUE RESEARCH FOUNDATION

Inventor： Philip S. Low ,  Isaac J. Marks ,  Spencer Gardeen ,  Sumith A. Kularatne

IPC: A61K51/04 ,  A61B90/00 ,  A61K47/54 ,  A61P35/00 ,  A61B5/00 ,  A61K31/395 ,  A61K31/454 ,  A61K31/537 ,  A61K49/00

Abstract: The present disclosure relates to compositions and methods of carbonic anhydrase IX inhibitors. The present disclosure also relates to targeting conjugates of carbonic anhydrase IX inhibitors. The present disclosure also relates to the use of targeting conjugates of carbonic anhydrase IX inhibitors in methods of treating disease and for imaging of disease.

公开(公告)号：US20210000962A1

公开(公告)日：2021-01-07

申请号：US16927773

申请日：2020-07-13

Applicant: Purdue Research Foundation ,  University of Utah

Inventor： Stewart Andrew Low ,  Philip S. Low ,  Christopher Galliford ,  Jindrich Kopecek ,  Jiyan Yang

IPC: A61K47/42 ,  A61L27/22 ,  A61L27/54 ,  C07K7/06 ,  C07K7/08 ,  A61P19/00 ,  A61K9/107 ,  A61K31/404 ,  A61M5/00

Abstract: Aspects of the present disclosure generally relate to compounds for targeting and healing bone fractures. Some of these compounds include a negatively charged oligopeptide comprising an acidic oligopeptide, a linker, which may be hydrolyzable or may be a substrate for the protease cathepsin K, and at least one molecule that promotes bone healing. In some compounds the molecule that promotes bone healing is an anabolic compound that inhibits GSK3β, in some compounds the molecule that promotes the healing of bone fracture is a pro-inflammatory agent such as PGE1. Other embodiments include methods of treating a bone fracture comprising administering a therapeutic amount of any one of the compounds disclosed herein.

公开(公告)号：US20200316174A1

公开(公告)日：2020-10-08

申请号：US16836366

申请日：2020-03-31

Applicant: Purdue Research Foundation

Inventor： Philip S. Low ,  Stewart A. Low ,  Jeffery Jay Howard Nielsen

IPC: A61K38/29 ,  A61K9/00 ,  A61P19/08

Abstract: Disclosed herein includes a drug delivery system comprising at least one peptide and a targeting ligand for bone fracture and/or for bone healing. Some embodiments include a peptide delivery system comprising at least an acidic, basic, hydrophilic, hydrophobic or neutral peptide linked to an acidic peptide or nonpeptidic polyanion for use in targeting the aforementioned attached peptide to a bone fracture surface. In some embodiments, a conjugated peptide expresses an anabolic function that acts through PTH receptor 1, and various formats of targeting ligands guide the drug to raw hydroxyapatite. This system offsets some side effects caused by free anabolic drug, such as high blood calcium concentration

公开(公告)号：US10765756B2

公开(公告)日：2020-09-08

申请号：US16105734

申请日：2018-08-20

Applicant: Purdue Research Foundation

Inventor： Philip S. Low ,  Charity Wayua

IPC: A61K49/00 ,  A61K47/54 ,  A61K31/4409 ,  A61K31/475 ,  C07D405/12 ,  C07D243/12 ,  A61K51/04 ,  A61K38/06 ,  A61K38/07 ,  A61K38/08 ,  A61K51/02

Abstract: Conjugates are described herein where CCK2R targeting ligands are attached to an active moiety, such as therapeutic agent or an imaging agent, through a linker. The conjugates can be used in the detection, diagnosis, imaging and treatment of cancer.